Predictive Oncology Inc. has announced new compensation terms, approving the grant of restricted stock units (RSUs) to key executives under the company's 2024 Equity Incentive Plan. On September 9, 2025, the Board of Directors awarded 124,959 RSUs to CEO Raymond F. Vennare and 97,000 RSUs to Interim CFO Josh Blacher. Each RSU entitles the holder to one share of the company's common stock upon vesting. The RSUs are set to fully vest by October 31, 2025, contingent upon continued service until that date.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Predictive Oncology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-25-005890), on September 12, 2025, and is solely responsible for the information contained therein.